A Phase 1/2 interventional study of NNC0662-3168 (Test product-A) and Placebo matched to NNC0662-3168 (Test product-A) in Overweight, Obesity and Type 2 Diabetes Mellitus, sponsored by Novo Nordisk A/S. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Novo Nordisk A/S · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 209 studies in Obesity by Novo Nordisk A/S — 50 open to participants now, 68 under way, 26 of them phase 3. Obesity · Novo Nordisk A/S.
Among the 209 studies in Obesity by Novo Nordisk A/S, this one is the 55th largest by planned enrollment of the 168 interventional ones that give a count, is one of 49 that started in 2026, is one of 2 in phase 1/2, reaches primary completion later than 39 of the 67 other live ones, and was the 208th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →50 of the 209 studies in Obesity by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in Austria
Ages 18–64
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in Germany
Ages 18+
By country, each count listing its studies:
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
209 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 88 · Phase 2 15 · Phase 3 62 · Phase 4 4
First in 2007; this study’s year is marked. 49 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 138 across the 168 interventional studies, 1,260 across the 41 observational. Of the 138 that completed or were terminated, 39 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,410 studies on the registry; 107 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
26 of the studies in Obesity by Novo Nordisk A/S that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07011667Phase 3Novo Nordisk A/SA Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | 2027-03-01 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07745504Phase 3Novo Nordisk A/SA Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | 2027-05-18 |
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
Add all 26 to your calendar (.ics) → With an account.
Among the 209 studies in Obesity by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn more about NNC0662-3168 as a potential treatment for people living with overweight or obesity and/or type 2 diabetes(T2D). The study will investigate its safety, tolerability and its effects in the body. The study will be conducted in four parts. Part A: Single Ascending Dose, Part B: Multiple Ascending Dose: Part C: Dose-finding in Weight Management. Part D: T2D proof-of-concept.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's planned enrollment of 300 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Novo Nordisk A/S is the lead sponsor of 1,410 studies on the registry; 107 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female (sex at birth).
Part D :
Exclusion Criteria:
For Part D:
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive NNC0662-3168 by subcutaneous injection in Part A to Part D.
Drug: NNC0662-3168 (Test product-A)
Participants will receive placebo by subcutaneous injection in Part A to Part C.
Drug: Placebo matched to NNC0662-3168 (Test product-A)
Participants will receive active comparator (product-B) by subcutaneous injection in Part C to Part D.
Drug: Active Comparator (Product-B)
NNC0662-3168 is administered subcutaneously.
Placebo is administered subcutaneously.
Active Comparator is administered subcutaneously.
Part A: Number of treatment-emergent adverse events (TEAEs)
Number of events.
Time frame: From dosing on day 1 upto 29 days
Part B: Number of treatment-emergent adverse events (TEAEs)
Number of events.
Time frame: From dosing at week 0 up to 39 weeks
Part C: Change in body weight
Measure in Percentage (%) change in body weight
Time frame: From baseline (week 0) to week 36
Part D: Change in glycated haemoglobin (HbA1c)
Measured in percentage of glycated haemoglobin.
Time frame: From baseline (week 0) to week 28
Part A: Area under the NNC0662-3168 concentration-time curve
Measured in hours times nanomole per litre ( h\*nmol/L).
Time frame: From pre-dose on day 1 upto 29 days
Part A: Maximum concentration of NNC0662-3168
Measured in nanomole per litre (nmol/L).
Time frame: From pre-dose on day 1 upto 29 days
Part B: Area under the NNC0662-3168 concentration-time curve
Measured in h\*nmol/L.
Time frame: From pre dose on day 1 upto 39 weeks
Part B: Maximum concentration of NNC0662-3168
Measured in nmol/L.
Time frame: From pre-dose on day 1 upto 39 weeks
Part C: Change in body weight (%)
Measured in percentage change in body weight
Time frame: From baseline (week 0) to week 36
Part C: Change in body weight (Kg)
Measured in kilogram
Time frame: From baseline to week 36
Part C: Body weight reduction greater than or equals to (≥) 5% (Yes/No)
Measured in Count of participants.
Time frame: From baseline (week 0) to week 36
Part C: Body weight reduction greater than or equals to (≥) 10% (Yes/No)
Measured in Count of participants.
Time frame: From baseline (week 0) to week 36
Part C : Body weight reduction greater than or equals to (≥) 15% (Yes/No)
Measured in Count of participants.
Time frame: From baseline (week 0) to week 36
Part C: Body weight reduction greater than or equals to (≥) 20% (Yes/No)
Measured in Count of participants.
Time frame: From baseline (week 0) to week 36
Part C: Body weight reduction greater than or equals to (≥) 25% (Yes/No)
Measured in Count of participants.
Time frame: From baseline (week 0) to week 36
Part C: Number of treatment-emergent adverse events (TEAEs)
Number of events.
Time frame: From dosing at week 0 to week 43
Part D: Change in fasting plasma glucose (FPG)
Measured in millimoles per litre (mmol/L).
Time frame: From baseline (week 0) to week 28
Part D: Change in homeostatic model assessment of insulin resistance (HOMA-IR)
Time frame: From baseline (week 0) to week 28
Part D: Change in time in range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL)
Measured in percentage points.
Time frame: From baseline (week -2 to week 0) to (week 26 to week 28)
Part D: Number of treatment-emergent adverse events (TEAEs)
Number of events.
Time frame: From dosing at week 0 to week 35
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Mar 2028, 16 months later.
Of 62 phase 1/2 interventional studies under Obesity, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's planned 16 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.